eGenesis, Inc.

We’re excited to announce our $191M Series D financing round led by Lux Capital with participation from existing investors ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, and Leaps by Bayer as well as new investors DaVita Kidney Care, Eisai US Innovation, NATCO Pharma and Parkwood Corporation. Proceeds will be used to advance the company’s lead product candidate, EGEN-2784, to a first-in-human study for kidney transplant. The funding will also be used to advance pipeline programs as well as scale production. Read the release: ???? https://lnkd.in/dU6QT-3E #organ #transplantation #biotech #funding

Thrilled to see?eGenesis, Inc.'s Wenning Qin and?Synchron's Riki Banerjee on? Fierce Biotech's 2024 Fiercest Women in Biotech List!??? https://lnkd.in/gciripAB

Congrats to our SVP Innovation Wenning Qin, who was nominated as one of Fierce Biotech's 2024 Fiercest Women in Life Sciences. Wenning Qin, Ph.D., became one of the world’s premier genome editors, at least in part, thanks to her firm understanding of animal breeding. Qin, senior vice president of innovation at eGenesis, has led her company’s efforts to engineer the pig genome to create a source of safe animal organs that can be transplanted into humans, a technique known as #xenotransplantation. But pigs are big, ravenous and long-lived—so scaling up a pig-breeding operation requires efficiency. Pigs genetically engineered by Qin and her team to have more humanlike kidneys have supplied organs that?kept a primate alive?for more than two years. And a pig-derived kidney from the company was transplanted into a patient with end-stage renal disease?for the first time?earlier this year. “This is a once-in-a-lifetime opportunity,” she said. “I really hope with the hard work here we’ll get to see the xeno organ going all the way to clinical launch and helping many who are in need of an organ.” Congratulations Wenning! We're proud to have you on the eGenesis team. Read the article for more about 10 of the most remarkable women in life sci, all of whom are redefining what it means to be truly fierce: https://lnkd.in/gciripAB

This year's Fiercest Women in Life Sciences special report is now live. Despite persistent barriers to equity, women continue to lead with incredible, groundbreaking work across pharma, biotech and medtech. Congratulations to the 2024 honorees! Eli Lilly and Company, Genentech, Mural Oncology, AstraZeneca, Schr?dinger, Novo Nordisk, Altoida, Inc., Synchron, Andreessen Horowitz, eGenesis, Inc.

We’re thrilled to announce today an exclusive clinical co-development agreement with OrganOx to advance a liver support system to facilitate liver recovery in the acute setting. ???? OrganOx’s normothermic machine perfusion (NMP) technology will be combined with eGenesis’ human-compatible, genetically engineered porcine livers to treat patients with liver failure. “We are excited to partner with OrganOx to address a critical unmet need for patients with liver failure,” said Michael Curtis, Ph.D., CEO of eGenesis. “This collaboration is a crucial step in our mission to develop safe and effective human-compatible organs for patients suffering from organ failure.” Read the release: https://lnkd.in/eUVXTnYE

We’re thrilled that our CEO Michael Curtis will be speaking on a panel about organ transplantation at the Boston Globe Media Future of Medicine conference this Wednesday on Nov 13. ???? The panel will be moderated by Adam Piore of the Boston Globe Media and joining Mike will be George Church and Tatsuo Kawai from MGH. More info for complimentary registration either in person or virtual: https://lnkd.in/e87Q3Ppx

Our CEO Michael Curtis will be speaking on a fireside chat at the UBS Virtual Organ Restoration and Cell Therapy Day on Tuesday, Oct. 15 at 12 pm ET. ???? The fireside chat will be moderated by Ashwani V. at UBS.

The field of #xenotransplantation, once relegated to the fringes of medicine, has grown by leaps and bounds over the past few years. Several companies in the United States, China, New Zealand and elsewhere are racing to breed and genetically engineer pigs so that their organs are better suited for human transplantation. Their aim — to fill the desperate need for organ transplants — is especially urgent when considering that in the United States alone, 17 people die each day waiting for an organ donation. Sharing this feature article in Nature Lab Animal, which features our CEO Michael Curtis and SVP, Innovation Wenning Qin who share their thoughts on where the challenges the field has overcome, and where it is heading next.

Nature Lab Animal speaks with our CEO Michael Curtis and SVP, Innovation Wenning Qin for this technology feature on organ transplantation. “The field of xenotransplantation, once relegated to the fringes of medicine, has grown by leaps and bounds over the past few years. Several companies in the United States, China, New Zealand and elsewhere are racing to breed and genetically engineer pigs so that their organs are better suited for human transplantation. Their aim — to fill the desperate need for organ transplants — is especially urgent when considering that in the United States alone, 17 people die each day waiting for an organ donation.” Read the article: ???? https://lnkd.in/eH8fkCK8

Thanks Wyss Institute at Harvard University for mentioning our work at eGenesis, Inc. ???? “In 2018, eGenesis launched from the Wyss and HMS to build on this feat in genome engineering, and further develop safe and effective pig organs as transplants for human patients. In the subsequent years, doctors from MGH, scientists from eGenesis, and Church continued to collaborate on this groundbreaking research.” Sharing the article: ???? https://lnkd.in/efX_G7Xn